Nerve Pain (Neuropathic Pain) Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Neuropathic pain is defined by the International Association for the Study of Pain (IASP) as 'pain arising as a direct consequence of a lesion or disease affecting the somatosensory nervous system.' Unlike nociceptive pain (a normal response to tissue injury), neuropathic pain reflects abnormal signalling within damaged or dysfunctional neural tissue — central, peripheral, or both.

Neuropathic pain affects approximately 7-10% of the general population (Bouhassira et al., Pain 2008), with higher prevalence in patients with diabetes (30%), herpes zoster survivors (10-15%), and HIV infection. It imposes a disproportionate burden of disability — neuropathic pain patients report greater interference with sleep, function, and quality of life compared to other chronic pain conditions.

Hallmark symptoms distinguishing neuropathic from nociceptive pain:

• Positive phenomena: Burning, electric-shock-like, or lancinating pain; allodynia (pain from normally non-painful stimuli — e.g., light touch from clothing); hyperalgesia (exaggerated pain response to normally mildly painful stimuli); spontaneous (stimulus-independent) shooting or stabbing pain.
• Negative phenomena: Sensory loss, numbness, hypersensitivity to temperature.
• Autonomic features: Skin colour and temperature changes, sudomotor dysfunction — especially in complex regional pain syndrome (CRPS).

Neuropathic pain is notoriously difficult to treat — unlike inflammatory pain, it responds poorly to conventional analgesics (paracetamol, NSAIDs) and requires specific pharmacological agents targeting central sensitisation and aberrant neural signalling pathways. Treatment is typically long-term, focused on meaningful pain reduction (goal: ≥30-50% reduction in NRS score) rather than elimination, with functional rehabilitation as the primary outcome measure.

Neuropathic pain arises from a wide range of peripheral and central nervous system pathologies:

Peripheral neuropathic pain:

• Diabetic peripheral neuropathy (DPN): Most common cause of neuropathic pain in high-income countries; affects 30% of patients with diabetes. Symmetrical distal stocking-and-glove distribution; burning, tingling, and allodynia in feet. Can be painful or painless (the latter is more common — accounts for the insidious risk of diabetic foot ulceration without warning pain).
• Post-herpetic neuralgia (PHN): Persistent neuropathic pain lasting >3 months after herpes zoster (shingles) rash resolution. Affects 10-15% of zoster patients; incidence increases steeply with age. Characterised by severe allodynia, burning pain, and dysaesthesia in the affected dermatome. Varicella zoster vaccination (Shingrix — recombinant zoster vaccine) reduces PHN risk by approximately 90% in vaccinated individuals.
• Trigeminal neuralgia (tic douloureux): Unilateral, paroxysmal, severe, electric-shock-like lancinating facial pain in the distribution of V2 (maxillary) and/or V3 (mandibular) branch of the trigeminal nerve; typically triggered by light touch (eating, talking, washing face). Most commonly caused by vascular compression of the trigeminal nerve root (superior cerebellar artery). Classified as Classical TN (vascular compression on MRI) or Idiopathic TN.
• Post-amputation phantom limb pain: 60-80% of amputees experience phantom limb pain; mechanism involves cortical reorganisation and peripheral sensitisation; management is multidisciplinary — mirror therapy, graded motor imagery, pharmacological treatment.
• Complex Regional Pain Syndrome (CRPS): CRPS Type I (no nerve injury — formerly reflex sympathetic dystrophy) and CRPS Type II (with nerve injury — formerly causalgia). Characterised by disproportionate pain, allodynia, autonomic dysfunction (colour/temperature/sweating changes), and trophic changes (skin/nail/hair abnormalities). Diagnosed by Budapest Criteria. Requires early aggressive multidisciplinary intervention to prevent chronification.
• Chemotherapy-induced peripheral neuropathy (CIPN): Caused by platinum compounds (oxaliplatin, cisplatin — most neurotoxic), taxanes (paclitaxel, docetaxel), vinca alkaloids, thalidomide/bortezomib. Causes symmetrical glove-and-stocking painful neuropathy; often limits chemotherapy dose intensity. Duloxetine is the only agent with RCT evidence for CIPN.
• HIV-associated sensory neuropathy: Direct HIV neurotropism plus antiretroviral drug toxicity (d4T, ddI); painful distal sensory neuropathy.
• Entrapment neuropathies: Carpal tunnel syndrome (median nerve), cubital tunnel (ulnar nerve), meralgia paraesthetica (lateral femoral cutaneous nerve) — burning pain and paraesthesiae in specific territories.
• Post-surgical neuropathic pain: Thoracotomy (intercostal nerve injury), mastectomy, inguinal herniorrhaphy, total knee replacement — chronic post-surgical pain with neuropathic features in 10-50% of major surgeries.

Central neuropathic pain:

• Central post-stroke pain (Dejerine-Roussy syndrome): Thalamic pain following stroke; burning, allodynic, continuous pain contralateral to stroke.
• Spinal cord injury pain: At-level and below-level burning, shooting pain; very difficult to treat; responds to pregabalin (evidence from Siddall RCT) and intrathecal therapies.
• Multiple sclerosis neuropathic pain: Lhermitte's phenomenon, painful spasms, central dysaesthesias.

Accurate diagnosis is essential — neuropathic pain is frequently under-diagnosed and mismanaged, leading to years of inadequate treatment:

Clinical diagnosis — the two-step approach:

1. Identify symptoms and signs consistent with neuropathic pain: Burning, electric shock pain, allodynia, hyperalgesia, autonomic features, sensory deficit, pain following dermatomal or nerve distribution.
2. Identify a neurological lesion or disease consistent with the pain distribution: Confirmation by history (diabetes, herpes zoster, surgery), clinical neurological examination, or neurophysiological testing (NCS/EMG, quantitative sensory testing — QST).

Screening tools (used for rapid clinical assessment):

• DN4 (Douleur Neuropathique 4 questions): Validated 10-item questionnaire (7 symptoms + 3 clinical signs); score ≥4/10 indicates likely neuropathic pain with 83% sensitivity and 90% specificity. Widely used in primary and secondary care.
• painDETECT: Patient self-reported 9-item questionnaire; particularly validated in low back pain and spine-related neuropathic pain; score ≥19 suggests neuropathic component.
• Leeds Assessment of Neuropathic Symptoms and Signs (LANSS): 7-item clinical scale combining patient report and bedside sensory testing; score ≥12/24 indicates neuropathic mechanism.

Neurophysiological investigations:

• Nerve conduction studies (NCS) and electromyography (EMG): Identify large-fibre neuropathy (reduced amplitudes, slowed conduction velocity); normal in small-fibre neuropathy.
• Skin punch biopsy (intraepidermal nerve fibre density — IENFD): Reduced IENFD confirms small-fibre peripheral neuropathy even when NCS is normal.
• Quantitative sensory testing (QST): Standardised psychophysical test battery assessing thermal, vibration, and pain thresholds; identifies sensory phenotypes to guide treatment selection.
• MRI neuroimaging: Essential for trigeminal neuralgia (visualise neurovascular compression), spinal cord injury pain, and central neuropathic pain conditions.

Who should be treated by a pain specialist: Trigeminal neuralgia refractory to carbamazepine; CRPS; spinal cord injury pain; post-stroke central pain; chemotherapy-induced neuropathy; any neuropathic pain unresponsive to 2 adequate trials of first-line agents; and candidates for neuromodulation (SCS, DRG stimulation).

NICE CG173 (2013, updated 2020) and NeuPSIG (2015) guidelines stratify treatment into first-, second-, and third-line categories:

First-Line Pharmacological Treatments:

• Duloxetine (serotonin-noradrenaline reuptake inhibitor — SNRI): 60mg once daily (start 30mg for first 2 weeks, then increase). The highest-evidence first-line agent specifically for diabetic peripheral neuropathy (multiple RCTs; NNT 5-6 for 50% pain relief). Also effective in chemotherapy-induced peripheral neuropathy (CIPN) — the only agent with RCT evidence for CIPN (Smith et al., JAMA 2013). Effective onset 2-4 weeks. Maximum licensed dose 120mg/day.
• Gabapentin (alpha-2-delta calcium channel subunit ligand): 300mg at night initially, titrated over 2-4 weeks to 1,800-3,600mg daily in 3 divided doses (or modified-release formulations). NNT approximately 7 for 50% pain reduction across neuropathic pain conditions; strongest evidence in PHN and DPN. Dose reduction required in renal impairment (eGFR-based).
• Pregabalin (alpha-2-delta ligand — faster onset than gabapentin, linear pharmacokinetics): 75mg twice daily initially, titrated to 150-300mg twice daily. Strong evidence base across PHN, DPN, spinal cord injury pain, and fibromyalgia. Faster and more predictable dose-response than gabapentin (no dose-dependent absorption saturation). Both gabapentin and pregabalin are Schedule 3 Controlled Drugs in the UK (Class C) due to misuse potential — prescribe with awareness of dependency.
• Amitriptyline (tricyclic antidepressant — TCA): 10mg nocte increasing to 25-75mg (analgesic doses lower than antidepressant doses). NICE CG173 includes amitriptyline alongside duloxetine and gabapentin/pregabalin as first-line options for any neuropathic pain. Particularly useful when comorbid insomnia and depression are present. Contraindicated in: recent MI, arrhythmia (prolonged QT), urinary retention, narrow-angle glaucoma, and elderly (Beers Criteria — anticholinergic burden).
• Note on NICE CG173 approach: Start with ONE first-line agent; if inadequate response at adequate dose and duration (6-8 weeks at target dose), switch to another first-line agent or add a second agent from a different class.

Second-Line Treatments:

• Tramadol (weak opioid + SNRI mechanism): 50-100mg up to 4x daily; NNT approximately 4 across neuropathic pain conditions. NICE CG173 recommends as second-line for acute exacerbations rather than long-term management; risk of dependency, serotonin syndrome (especially with duloxetine — avoid combination), and seizure threshold lowering. Schedule 3 controlled drug in the UK.
• Lidocaine 5% medicated plaster (Versatis): Applied to the painful area for up to 12 hours per day. Evidence primarily in PHN; localised allodynia responds well. NICE-approved for PHN; benefits: minimal systemic absorption, well tolerated in elderly, can be applied to allodynic skin. Available in UK via specialist initiation; expensive relative to oral agents.
• Capsaicin 8% patch (Qutenza): Applied by a healthcare professional under topical anaesthesia (EMLA cream) for 60 minutes to the pain area; causes rapid desensitisation of TRPV1 (transient receptor potential vanilloid 1) receptors on nociceptive C-fibres through selective depletion of substance P and transient nerve fibre retraction. RCT evidence (CAPS trials): approximately 30% of patients achieve ≥30% pain reduction and approximately 30% achieve ≥50% reduction in PHN; treatment effect lasts approximately 3 months. Approved for peripheral neuropathic pain in non-diabetic adults; single application procedure; re-treatment every 3 months. In the UK, administered in secondary/tertiary pain clinic settings.

Condition-Specific Treatments:

Trigeminal Neuralgia:

• Carbamazepine 200-1,600mg daily: First-line treatment; NNT 1.9 — the most effective pharmacological treatment for any neuropathic pain condition. Mechanism: voltage-gated sodium channel blockade. Monitor sodium (risk of hyponatraemia, SIADH), CBCs (agranulocytosis — rare), and liver function. HLA-B*1502 screening before initiation in South Asian and Chinese populations (Stevens-Johnson syndrome risk).
• Oxcarbazepine 600-1,800mg daily: Better tolerated than carbamazepine (fewer drug interactions, lower risk of aplastic anaemia and Stevens-Johnson); increasingly preferred as first-line in many centres.
• Refractory TN (failed carbamazepine): Surgical options — Microvascular Decompression (MVD): neurosurgical posterior fossa approach to decompress the trigeminal nerve from the offending vessel with a Teflon felt pad; 70-80% immediate pain-free rate; 60-70% remain pain-free at 10 years (best long-term outcomes of all TN procedures). Stereotactic radiosurgery (Gamma Knife): Non-invasive; target the trigeminal nerve root entry zone with 70-90Gy; 70-80% initial response; 50% pain-free at 3 years without medication; delayed onset (weeks to months). Percutaneous procedures (glycerol rhizolysis, balloon compression, radiofrequency thermocoagulation): Immediate effect; higher recurrence rates; suitable for elderly/frail patients not fit for MVD.

Complex Regional Pain Syndrome (CRPS):

• Multidisciplinary approach is essential — physiotherapy (graded motor imagery, mirror therapy, desensitisation), occupational therapy, psychology (CBT, acceptance and commitment therapy), and pharmacotherapy.
• Pharmacological: bisphosphonates (alendronate, pamidronate — RCT evidence for CRPS-I; reduce bone resorption and pain); corticosteroids (short courses in acute-phase CRPS); nalmefene (naltrexone) — low-dose naltrexone for neuroinflammatory modulation; gabapentinoids; ketamine infusion.
• Ketamine infusion: NMDA receptor antagonist; low-dose ketamine infusions (0.1-0.5mg/kg/hour IV over 3-5 days) provide 60-80% temporary pain relief in refractory CRPS (open-label evidence; RCT data limited). Dissociative psychedelic effect managed with benzodiazepine pretreatment; specialist inpatient or day-unit setting required.
• Spinal cord stimulation: strong evidence for CRPS (see Neuromodulation below).

Neuromodulation (Third-Line / Specialist Centre):

• Spinal Cord Stimulation (SCS): Epidurally placed electrode at the dorsal column; electrical stimulation produces paresthesia overlapping the neuropathic pain territory. Established by landmark RCTs: PROCESS trial (Kumar et al., Lancet 2007): SCS + physiotherapy vs physiotherapy alone for failed back surgery syndrome with leg pain — SCS group had 48% vs 9% achieving ≥50% pain relief at 6 months. SENZA-RCT (Kapural et al., Anesthesiology 2015): High-frequency SCS (10kHz — HF10, Nevro) vs conventional SCS — HF10 produced superior pain relief (85% vs 44% responder rates for back pain) without paresthesia. Current SCS technology includes burst stimulation (De Ridder waveform), dorsal root ganglion stimulation, and closed-loop adaptive SCS.
• Dorsal Root Ganglion (DRG) Stimulation: Electrode placed at the DRG level providing highly focal coverage of specific pain territories (groin, foot, knee) where conventional SCS paresthesia coverage is difficult. The ACCURATE trial demonstrated superiority of DRG stimulation over SCS for complex regional pain syndrome of the lower extremity (81% vs 56% composite success rate). Particularly valuable for CRPS, post-surgical neuralgia, and focal neuropathic pain territories.

Realistic expectations are important — the goal of neuropathic pain treatment is meaningful pain reduction (defined as ≥30% or ≥50% reduction from baseline NRS score) plus functional improvement, not complete pain elimination:

• Duloxetine (DPN): NNT for ≥50% pain relief = 5-6; approximately 40-50% of patients achieve clinically meaningful response. Superior tolerability vs TCAs in elderly diabetic patients.
• Gabapentin (PHN/DPN): NNT approximately 7 across conditions; effective in 40-50% at therapeutic doses. Dose-response relationship requires adequate titration to 2,400-3,600mg/day to assess true efficacy.
• Amitriptyline: NNT approximately 4-5 across neuropathic pain conditions; particularly effective when sleep disturbance is prominent. Often more cost-effective than newer agents; NNT superior to gabapentin in some meta-analyses.
• Carbamazepine (trigeminal neuralgia): NNT 1.9 — the best pharmacological NNT in neuropathic pain; 70-80% of TN patients respond initially, but long-term efficacy wanes due to tolerance and side effects; 30-40% eventually require surgical intervention.
• Capsaicin 8% patch (Qutenza — PHN): 30% of patients achieve ≥30% pain reduction; treatment lasts approximately 3 months per application; eliminates need for daily oral medications in responders — major quality of life advantage.
• Spinal cord stimulation (PROCESS trial): 48% vs 9% SCS vs physiotherapy responder rates at 6 months for failed back surgery syndrome with radiculopathy; 75% of responders maintained benefit at 5 years. SCS is cost-effective vs continued medical management when response is sustained — device pays for itself within 2.5 years (UK NHS cost-effectiveness analysis).
• DRG stimulation (ACCURATE trial): 81% composite success (CRPS lower limb) vs 56% with conventional SCS at 3 months; maintained at 12 months; improved function and quality of life.
• Ketamine infusion (CRPS): 60-80% temporary pain relief; duration 6-12 weeks; may be repeated; particularly valuable as bridge therapy during rehabilitation.

Duloxetine (SNRI): Nausea (30% — reduced by taking with food and starting at 30mg), insomnia, dizziness, dry mouth, constipation, urinary hesitancy, hypertension (dose-related), and sexual dysfunction. Risk of serotonin syndrome with concurrent tramadol, SSRIs, or triptans. Abrupt discontinuation syndrome (brain zaps, dizziness, flu-like symptoms) — taper over 2-4 weeks. Caution in liver impairment and uncontrolled hypertension.

Gabapentin and pregabalin (alpha-2-delta ligands): Dizziness (30%), somnolence (25%), peripheral oedema (10-15%), weight gain (particularly pregabalin with longer-term use), cognitive slowing, and blurred vision. Falls risk in elderly — start low (100-150mg) and titrate slowly. Dependency and misuse potential (Schedule 3 / Class C in UK since 2019) — withdrawal seizures reported with abrupt cessation at high doses; taper over 2-4 weeks. Dose reduction essential in renal impairment (both drugs are renally cleared).

Amitriptyline (TCA): Anticholinergic effects (dry mouth, constipation, urinary retention, blurred vision, confusion in elderly), sedation (morning hangover — take 2 hours before sleep), postural hypotension, cardiac arrhythmia (QT prolongation — contraindicated if pre-existing arrhythmia), and weight gain. ECG before prescribing in patients >65 or with cardiac history. Potentially lethal in overdose (wide QRS, arrhythmia) — exercise caution in patients at suicide risk.

Carbamazepine (TN): Diplopia, dizziness, ataxia (dose-related — particularly problematic in elderly), hyponatraemia (SIADH — monitor sodium; significant risk in those on diuretics), myelosuppression (aplastic anaemia — rare but potentially fatal; baseline FBC + monitoring), hepatotoxicity (monitor LFTs), drug interactions via CYP3A4 induction (reduces efficacy of warfarin, OCP, other AEDs), Stevens-Johnson syndrome (HLA-B*1502 screening in high-risk ethnic populations).

Tramadol: Nausea, constipation, dizziness, seizure threshold lowering (caution in epilepsy), serotonin syndrome (with SSRIs/SNRIs — particularly duloxetine; co-prescription generally discouraged), dependency and withdrawal; Schedule 3 CDS in UK; misuse potential.

Lidocaine patch (Versatis): Local skin reactions (erythema, rash at application site); minimal systemic lidocaine absorption (plasma level <0.1% of antiarrhythmic dose); rare systemic lidocaine toxicity (tingling, cardiac arrhythmia — only if applied to large broken skin areas).

Capsaicin 8% patch (Qutenza): Application site pain (most common — intense burning during and after 60-minute application; managed with local cooling and short-acting analgesics), erythema, and oedema. Transient. Eye and mucous membrane contact must be avoided (severe burning). Brief initial pain increase is typical and expected; persists 1-3 days then pain reduces.

Spinal cord stimulation: Surgical risks — infection (<3%), epidural haematoma (<0.5%), lead migration or fracture (5-10% per year), device revision surgery required in 30-40% at 5 years. Spinal cord injury from epidural haematoma or direct electrode trauma (rare, <0.1%). MRI compatibility depends on device model — newer implants have conditional MRI approval. Battery replacement (IPG) every 5-15 years (rechargeable IPG reduces revision frequency).

Ketamine infusion: Dissociative psychedelic effects (managed with benzodiazepine); hypertension and tachycardia during infusion; emergence reactions; potential for psychological dependency with repeated use; concerns about ketamine-associated uropathy (bladder damage) with very frequent long-term use (lower risk at analgesic subanesthetic doses vs recreational use).

Neuropathic pain requires structured, proactive follow-up with regular reassessment of pain intensity, functional outcomes, adverse effects, and treatment escalation:

Initial pharmacotherapy initiation:

• Adequate trial: Allow 6-8 weeks at therapeutic target dose before assessing treatment response — premature discontinuation is a common error.
• Pain diary: Patient records daily NRS pain score (0-10), sleep quality, and functional capacity to track trends.
• Review at 2-4 weeks: Assess tolerability, titration progress, and early benefit signal. Address side effects proactively (e.g., morning sedation with amitriptyline — adjust timing; nausea with duloxetine — take with food).
• Review at 6-8 weeks: Full efficacy assessment. If ≥50% pain reduction: continue and maintain. If 30-50% partial response: consider adding a second first-line agent from a different class (e.g., add amitriptyline to gabapentin; both acting via different mechanisms — additive effect). If <30% response: switch to another first-line agent or refer to pain specialist.

Ongoing monitoring (pharmacotherapy):

• Gabapentinoids: Monitor for dependency signs; annual review of ongoing need; sodium levels in elderly on carbamazepine; renal function annually to adjust gabapentinoid doses.
• Amitriptyline: ECG at baseline (>65 or cardiac history); review medication burden; regular anticholinergic burden assessment in elderly.
• Duloxetine: Blood pressure (may rise 2-4 mmHg); LFTs in chronic alcohol use; assess mood (SNRI may improve comorbid depression).

Post-SCS implant follow-up:

• Programming: Multiple stimulation sessions (weeks 1, 4, 3 months, 6 months) to optimise electrode configuration, amplitude, frequency, and waveform for best coverage.
• Trial period assessment (7-14 days with external pulse generator): If ≥50% pain reduction, proceed to permanent IPG implantation.
• Annual follow-up: Battery status check (recharge schedule for rechargeable devices), lead position X-ray if new or changed symptoms, pain score reassessment, functional outcomes review.

Multidisciplinary pain programme (CRPS and refractory neuropathic pain):

• Structured 4-8 week intensive programme incorporating graded exercise, CBT, pain education, occupational therapy, and psychology.
• Key goals: Improve function and acceptance; reduce kinesiophobia and catastrophising; achieve sustainable self-management strategies independent of medication.

CRPS-specific follow-up:

• Early intensive physiotherapy is the most important prognostic factor in CRPS — avoid immobilisation.
• Monitor for sympathetically maintained vs sympathetically independent pain (diagnostic sympathetic block).
• Budapest Criteria reassessment at 3 and 12 months to track disease evolution.

Neuropathic pain treatment spans from very low-cost generic medications to high-cost neuromodulation devices:

First-line medications (monthly cost estimates):

• Amitriptyline 10-75mg: UK NHS £1-3/month; USA generic $5-15/month; India ₹50-200/month — highly cost-effective.
• Gabapentin 1,800-3,600mg: UK NHS (generic) £10-25/month; USA generic $30-80/month; India ₹200-500/month.
• Pregabalin 150-300mg twice daily: UK NHS (generic post-patent) £10-30/month; USA generic $40-120/month; brand Lyrica was >$500/month (USA) until generic availability.
• Duloxetine 60mg: UK NHS (generic) £5-15/month; USA generic $20-60/month; India ₹300-600/month.
• Carbamazepine 200-800mg twice daily: UK NHS £5-15/month; USA generic $15-40/month; India ₹100-300/month.

Second-line and specialist treatments:

• Lidocaine 5% medicated plaster (Versatis): UK NHS £40-60/month (specialist-initiated only); USA $150-250/month.
• Capsaicin 8% patch (Qutenza): Single patch application UK NHS £210 (procedure cost £400-600 including clinic); USA $600-900 per patch plus clinic. Repeatable every 3 months; cost-effective if oral medications are not tolerated or ineffective.
• Ketamine infusion (5-day CRPS programme): UK private £1,500-3,000; USA $3,000-8,000; India ₹30,000-80,000 per course.

Neuromodulation costs:

• Spinal cord stimulation: Device cost (IPG + leads): £10,000-20,000 (UK); $20,000-40,000 (USA). Total implant cost (device + surgeon + hospital): UK NHS SCS programme approximately £30,000-50,000 first year (incl. trial); USA $80,000-150,000. India: ₹5,00,000-12,00,000 (device + surgery). NHS considers SCS cost-effective for failed back surgery syndrome at <£10,000/QALY — well within the NICE threshold of £20,000-30,000/QALY.
• DRG stimulation: Device cost 15-25% higher than SCS; total cost UK private £35,000-60,000; USA $90,000-180,000; India ₹7,00,000-15,00,000.

Trigeminal neuralgia surgery:

• MVD (microvascular decompression): UK private £12,000-18,000; USA $25,000-45,000; India ₹2,00,000-5,00,000.
• Gamma Knife radiosurgery: UK private £10,000-15,000; USA $15,000-30,000; India ₹2,00,000-4,00,000.

Complementary therapies may be used as adjuncts or alternatives in patients where pharmacotherapy is limited by tolerability:

• Transcutaneous Electrical Nerve Stimulation (TENS): Low-risk, low-cost, patient-controlled neuromodulation; moderate evidence for neuropathic pain reduction in DPN and PHN; considered acceptable adjunct by NICE; conventional (high frequency/low intensity) vs acupuncture-like TENS (low frequency/high intensity) modes. Most effective for localised neuropathic pain.
• Acupuncture: Cochrane reviews find weak-to-moderate evidence for peripheral neuropathic pain (DPN, PHN) and trigeminal neuralgia; not recommended as standalone treatment by NICE CG173 but widely integrated in pain clinic settings; generally well tolerated.
• Mirror therapy and graded motor imagery (CRPS/phantom limb): High-quality evidence for CRPS and phantom limb pain — mirror box visual feedback tricks the brain into perceiving a painful limb as normal; reduces cortical reorganisation driving pain. First-line non-pharmacological therapy for CRPS and post-amputation phantom pain.
• Cognitive Behavioural Therapy (CBT): Strong evidence base for chronic pain including neuropathic conditions; addresses pain catastrophising, kinesiophobia, sleep disturbance, and comorbid depression/anxiety. Most effective as part of a multidisciplinary pain programme rather than standalone.
• Mindfulness-Based Stress Reduction (MBSR): Reduces pain unpleasantness and psychological distress; particularly effective for central sensitisation and chronic widespread neuropathic pain.
• Transcranial Magnetic Stimulation (TMS) and transcranial Direct Current Stimulation (tDCS): Non-invasive brain stimulation targeting motor cortex or dorsolateral prefrontal cortex; emerging evidence for neuropathic pain reduction (central post-stroke pain, fibromyalgia); available in some tertiary pain centres; not yet NICE-approved as standard treatment.
• Platelet-Rich Plasma (PRP) injections: Emerging evidence for entrapment neuropathies (carpal tunnel, cubital tunnel); promotes nerve regeneration; not yet standard of care — offered in musculoskeletal medicine centres.
• Scrambler therapy: A novel neurocutaneous electrostimulation approach delivering 'non-pain' information via the same pain pathways; Phase II RCT evidence for CIPN and PHN; not yet widely available.
• Intrathecal drug delivery (pain pump): Continuous intrathecal delivery of morphine, ziconotide (N-type calcium channel blocker — specifically approved for intrathecal use), or clonidine for refractory severe neuropathic pain; achieves analgesia at 1/300th the systemic dose; used in specialist centres for CRPS, spinal cord injury pain, and cancer-related neuropathic pain.